Gilead Sciences, Inc. (GILD)
Largest Insider Buys in Sector
GILD Stock Price History Chart
GILD Stock Performance
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, …
Insider Activity of Gilead Sciences, Inc.
Over the last 12 months, insiders at Gilead Sciences, Inc. have bought $0 and sold $50.09M worth of Gilead Sciences, Inc. stock.
On average, over the past 5 years, insiders at Gilead Sciences, Inc. have bought $0 and sold $13.73M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $2M was made by WOLD OLSEN PER (director) on 2015‑02‑06.
List of Insider Buy and Sell Transactions, Gilead Sciences, Inc.
| 2024-12-16 | Sale | Chief Financial Officer | 8,500 0.0007% | $91.96 | $781,660 | +0.69% | ||
| 2024-11-29 | Sale | Chief Financial Officer | 248,645 0.02% | $92.76 | $23.07M | -0.22% | ||
| 2024-11-27 | Sale | Chief Medical Officer | 164,211 0.0131% | $91.92 | $15.09M | -0.03% | ||
| 2024-11-26 | Sale | director | 6,788 0.0005% | $91.39 | $620,356 | +1.13% | ||
| 2024-11-06 | Sale | Chief Medical Officer | 25,590 0.0021% | $91.50 | $2.34M | +0.75% | ||
| 2024-11-06 | Sale | Chief Commercial Officer | 5,000 0.0004% | $91.28 | $456,400 | +0.75% | ||
| 2024-10-01 | Sale | Chief Medical Officer | 2,000 0.0002% | $83.83 | $167,660 | +7.62% | ||
| 2024-09-12 | Sale | Chief Medical Officer | 21,246 0.0017% | $84.50 | $1.8M | +7.69% | ||
| 2024-09-12 | Sale | Chief Commercial Officer | 29,357 0.0024% | $83.78 | $2.46M | +7.69% | ||
| 2024-08-28 | Sale | Chief Commercial Officer | 9,513 0.0008% | $78.03 | $742,299 | +11.20% | ||
| 2024-08-13 | Sale | Chief Commercial Officer | 5,490 0.0004% | $73.98 | $406,150 | 0.00% | ||
| 2024-07-01 | Sale | Chief Medical Officer | 2,000 0.0002% | $68.63 | $137,260 | 0.00% | ||
| 2024-04-01 | Sale | Chief Medical Officer | 2,000 0.0002% | $72.96 | $145,920 | +4.14% | ||
| 2024-02-29 | Sale | Chief Medical Officer | 8,230 0.0007% | $72.74 | $598,624 | +2.94% | ||
| 2024-02-28 | Sale | Chief Medical Officer | 2,000 0.0002% | $73.18 | $146,360 | +2.05% | ||
| 2024-01-16 | Sale | Chief Financial Officer | 5,000 0.0004% | $85.78 | $428,900 | -13.30% | ||
| 2024-01-09 | Sale | Chief Commercial Officer | 8,242 0.0007% | $85.23 | $702,466 | -13.48% | ||
| 2023-10-17 | Sale | Chief Financial Officer | 5,000 0.0004% | $80.00 | $400,017 | -6.68% | ||
| 2023-09-12 | Sale | Chief Medical Officer | 1,501 0.0001% | $76.99 | $115,562 | -2.57% | ||
| 2023-07-20 | Sale | Chief Financial Officer | 5,000 0.0004% | $80.00 | $400,000 | -5.94% |
Insider Historical Profitability
| MARTIN JOHN C | director | 2877762 0.2309% | $92.57 | 1 | 157 | +15.06% |
| MILLIGAN JOHN F | President and CEO | 1165924 0.0936% | $92.57 | 1 | 53 | +12.4% |
| WOLD OLSEN PER | director | 97854 0.0079% | $92.57 | 4 | 3 | +18.87% |
| HILLS CARLA A | director | 2742 0.0002% | $92.57 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $8.98B | 9.84 | 122.53M | -0.21% | -$19.19M | 0.2 | |
| The Vanguard Group | $8.4B | 9.21 | 114.73M | +2.6% | +$213.17M | 0.16 | |
| Capital World Investors | $6.19B | 6.78 | 84.5M | +1.36% | +$83.01M | 1.03 | |
| Capital Research Global Investors | $4.49B | 4.92 | 61.25M | +2.66% | +$116.41M | 1.02 | |
| State Street | $4.23B | 4.63 | 57.7M | -3.08% | -$134.16M | 0.17 |